Soluble P-selectin as a potential diagnostic and prognostic biomarker for COVID-19 disease: A case-control study

Karslı, Emre; Sabırlı, Ramazan; Altıntaş, Emel; Çanacık, Ömer; Sabirli, Gizem Tukenmez; Kaymaz, Buse; Kurt, Özgür; Köseler, Aylin

doi:10.1016/j.lfs.2021.119634

Cited by 28 publications

(27 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have investigated whether laboratory parameters such as monocyte/lymphocyte ratio, CRP, ferritin, lactate dehydrogenase (LDH), interleukin‐6 (IL‐6), D‐dimer, p selectin, calprotectin, and surfactant can be used as biomarkers for the clinical diagnosis and prediction of prognosis for COVID‐19. 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 The sensitivity of the markers for COVID‐19 diagnosis mentioned in these studies ranged between 66% and 97.5%. 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 …”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Annexin A1 as a potential prognostic biomarker for COVID‐19 disease: Case–control study

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Annexin A1 (AnxA1) is an important endogenous glucocoticoid protein that contributes to the suppression of inflammation by limiting the production of neutrophil and pro‐inflammatory cytokines. This study aims to determine the clinical predictivity value of blood AnxA1 levels in patients with mild and severe–critical pneumonia induced by COVID‐19. Methods This study employed a prospective, case–control study design and was conducted at Ankara Training and Research hospital between 10 February 2021 and 15 March 2021. A total of 74 patients (42 of whom had moderate and 32 of whom had severe/critical cases of COVID‐19 disease according to World Health Organization guidelines) and 50 nonsymptomatic healthy volunteers participated in the study. Blood samples were taken from patients at the time of hospital admission, after which serum was isolated. Following the isolation of serum, AnxA1 levels were evaluated using the enzyme‐linked immunosorbent assay method. Results The serum AnxA1 levels were measured as 25.5 (18.6‐38.6) ng/ml in the control group, 21.2 (14.7‐32) ng/ml in the moderate disease group, and 14.8 (9.7‐26.8) ng/ml in the severe/critical disease group. Serum AnxA1 levels were significantly lower in the severe/critical disease group compared with the control and moderate disease groups ( P = .01 and P = .0001, respectively). Using receiver operating characteristic analysis, a larger area under the curve (AUC) for the serum AnxA1 levels of the control group (AUC = 0.715, 95% CI = 0.626‐0.803; P = .0001) was calculated compared with the COVID‐19 patient group for the diagnosis of COVID‐19 disease. The AnxA1 level was found to be 80% sensitive and 54.1% specific at a cut‐off level of 18.5 ng/ml for the diagnosis of COVID‐19 disease. Moreover, the AnxA1 level was found to be 69.8% sensitive and 58.1% specific at a cut‐off level of 17.2 ng/ml in predicting the need for intensive care unit (ICU) treatment. Conclusion AnxA1 levels may be a beneficial biomarker in the diagnosis of COVID‐19 pneumonia and in predicting the need for ICU treatment in patients with COVID‐19 pneumonia at the time of admission to the emergency department.

show abstract

Section: Discussionmentioning

confidence: 94%

“… 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 The sensitivity of the markers for COVID‐19 diagnosis mentioned in these studies ranged between 66% and 97.5%. 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 …”

Section: Discussionmentioning

confidence: 94%

Annexin A1 as a potential prognostic biomarker for COVID‐19 disease: Case–control study

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Platelets from COVID-19 patients also aggregated more quickly and distributed more widely by fibrinogen and collagen. [ 51 ] Five studies found higher values in COVID-19 ICU patients compared with severe non-ICU COVID-19 patients [ 52 , 53 , 54 , 55 , 56 ]. SARS-CoV-2 interacts with platelets and megakaryocytes via an ACE2-independent mechanism, according to Shen et al [ 52 ], and may influence alternative receptor expression linked with COVID-19 coagulation abnormalities.…”

Section: Resultsmentioning

confidence: 99%

“…COVID-19 + patients had exacerbated and chronic endothelium damage, as evidenced by raised sP-sel. Karsli et al [ 56 ] focused on the diagnostic and predictive relevance of serum soluble sP-Sel levels in COVID-19 illness and found that patients with mild-to-moderate and severe pneumonia had greater serum sP-Sel levels than those with no pneumonia. At the cut-off level of 4.125 ng/ml, sP-Sel levels were reported to be 97.5 percent sensitive and 80 percent specific in the diagnosis of COVID-19.…”

Section: Resultsmentioning

confidence: 99%

The Role of P-Selectin in COVID-19 Coagulopathy: An Updated Review

Agrati

Sacchi

Tartaglia

et al. 2021

IJMS

View full text Add to dashboard Cite

In severe COVID-19, which is characterized by blood clots and neutrophil-platelet aggregates in the circulating blood and different tissues, an increased incidence of cardiovascular complications and venous thrombotic events has been reported. The inflammatory storm that characterizes severe infections may act as a driver capable of profoundly disrupting the complex interplay between platelets, endothelium, and leukocytes, thus contributing to the definition of COVID-19-associated coagulopathy. In this frame, P-selectin represents a key molecule expressed on endothelial cells and on activated platelets, and contributes to endothelial activation, leucocyte recruitment, rolling, and tissue migration. Briefly, we describe the current state of knowledge about P-selectin involvement in COVID-19 pathogenesis, its possible use as a severity marker and as a target for host-directed therapeutic intervention.

show abstract

“…The expression level of sPselectin is considered a biomarker of inflammation, platelet activation, and vascular and thrombotic diseases. [42][43][44] To reveal the correlation of THCMA's P-selectin inhibition activity with its antithrombosis, anti-inflammation, and antitumor activity, in vivo expression levels of sP-selectin and TNFα were examined. Figure 8A-D show that expression levels of sP-selectin in arterial thrombosis rats, venous thrombosis rats, S180 mice, and ear-edema mice had similar patterns.…”

Section: Downregulation Of Sp-selectin and Tnfα Expression By Thcma In Vivomentioning

confidence: 99%

Nanoparticles of a New Small-Molecule P-Selectin Inhibitor Attenuate Thrombosis, Inflammation, and Tumor Growth in Two Animal Models

Feng¹,

Wang²,

Muhtar³

et al. 2021

IJN

View full text Add to dashboard Cite

Purpose: To assess whether the newly designed small-molecule oral P-selectin inhibitor 3S-1,2,3,4-tetrahydro-β-carboline-3-methyl aspartyl ester (THCMA) as a nanomedicine enhances antithrombosis, anti-inflammation, and antitumor activity more than the clinical trial drug PSI-697. Methods: THCMA was designed as an amphiphile containing pharmacophores of PSI-697. Its nanofeatures were explored with TEM, SEM, Tyndall effect, ζ-potential, FT-ICR-MS, and NOESY 2D 1 H NMR. The P-selectin inhibitory effect of THCMA was demonstrated with molecular docking, ultraviolet (UV) spectra, and competitive ELISA. In vivo and in vitro assays -anti-arterial thrombosis, anti-venous thrombosis, anti-inflammation, antitumor growth, anti-platelet aggregation, rat-tail bleeding time, anticoagulation index, soluble P-selectin (sP-selectin) expression, and serum TNFα expression -were performed to explore bioactivity and potential mechanisms. Water solubility of THCMA was measured using UV-absorption spectra. Results: THCMA self-assembled into nanorings of approximately 100 nm in diameter. Its water solubility was about 1,030-fold that of PSI-697. THCMA exhibited more potent P-selectin inhibitory effect than PSI-697. The oral efficacy of THCMA was 100-fold that of PSI-697 in inhibiting arterial and venous thrombosis and tenfold in inhibiting inflammation. THCMA inhibited thrombosis at a dose that produces no coagulation disorders and no bleeding risk. THCMA exhibited enhanced antitumor activity over PSI-697 without systemic chemotherapy toxicity. THCMA significantly inhibited platelet aggregation in vitro and downregulated the expression levels of serum sP-selectin and TNFα in vivo. Conclusion:A new small-molecule P-selectin inhibitor, THCMA, has been successfully designed as a nanomedicine with largely enhanced oral efficacy compared to the clinical trial drug PSI-697, and thus might be developed for the oral treatment of arterial thrombosis, venous thrombosis, inflammation, and cancer-associated thrombosis.

show abstract

Soluble P-selectin as a potential diagnostic and prognostic biomarker for COVID-19 disease: A case-control study

Cited by 28 publications

References 39 publications

Annexin A1 as a potential prognostic biomarker for COVID‐19 disease: Case–control study

Annexin A1 as a potential prognostic biomarker for COVID‐19 disease: Case–control study

The Role of P-Selectin in COVID-19 Coagulopathy: An Updated Review

Nanoparticles of a New Small-Molecule P-Selectin Inhibitor Attenuate Thrombosis, Inflammation, and Tumor Growth in Two Animal Models

Contact Info

Product

Resources

About